Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA Reproductive Health Drugs Advisory Committee

Executive Summary

FDA Reproductive Health Drugs Advisory Committee: Postcoital emergency use of "certain" oral contraceptives will be discussed by committee (formerly the Fertility & Maternal Health Drugs Advisory Committee) June 28. FDA received a citizen's petition from the Center for Reproductive Law & Policy in November 1994 requesting inclusion of the use in OC labeling. FDA denied the petition but "determined that it would be appropriate to discuss the scientific issues related to the safety and effectiveness of this use." The meeting will begin at 9 a.m. at the Holiday Inn, Gaithersburg, Md...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel